Navigation Links
Amylin Pharmaceuticals to Present at Goldman Sachs 32nd Annual Global Healthcare Conference and Jefferies Global Life Sciences Conference
Date:5/31/2011

SAN DIEGO, May 31, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Goldman Sachs 32nd Annual Global Healthcare Conference on Tuesday, June 7, 2011, at 12:20 p.m. ET / 9:20 a.m. PT in Palos Verdes, California and at the Jeffries Global Life Sciences Conference on Wednesday, June 8, 2011, at 10:00 a.m. ET / 7:00 a.m. PT in New York.  Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview at the Goldman Sachs conference.  Mark Foletta, senior vice president, finance and chief financial officer of Amylin, will provide a corporate overview at the Jeffries conference.

The presentations will be webcast live through the "Investors" section of Amylin's corporate website at www.amylin.com, and the recordings will be made available on the website following the events. To access the live webcasts, please log on to Amylin's website approximately fifteen minutes prior to the presentations to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin to Advance Key Value-Driving Opportunities in 2011
2. Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin
3. Amylin Pharmaceuticals to Present at the Citi 7th Annual US Small/Mid Cap Conference
4. Amylin Pharmaceuticals Announces Third Quarter Product Revenues; Quarterly Update Conference Call Canceled
5. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
6. Amylin Pharmaceuticals to Present at the 2010 Jefferies Global Life Sciences Conference
7. Amylin Pharmaceuticals to Present at the 2010 Citi Investment Research Global Healthcare Conference
8. Amylin Pharmaceuticals to Present at the Deutsche Bank 35th Annual Healthcare Conference
9. Amylin Pharmaceuticals to Webcast Third Quarter Results
10. Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009
11. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks ... to industrial engineering, was today awarded as one ... selection of the world,s most innovative companies. Ginkgo ... scale for the real world in the nutrition, ... engineers work directly with customers including Fortune 500 ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/24/2016)... ... 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona ... or pleural mesothelioma. Their findings are the subject of a new article on the ... are signposts in the blood, lung fluid or tissue of mesothelioma patients that can ...
(Date:6/23/2016)... ... 2016 , ... UAS LifeSciences, one of the leading manufacturers ... Probiotics, into Target stores nationwide. The company, which has been manufacturing high quality ... list of well-respected retailers. This list includes such fine stores as Whole Foods, ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
Breaking Biology News(10 mins):